Exeligen Scientific Overview

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Exeligen Scientific General Information

Description

Developer of a genome editing technology. The company offers genomic engineering products and services such as clustered regularly inter-spaced short palindromic repeats, CRISPR and Cas-related systems.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 5505 Lakeview Canyon Road
  • Westlake Village, CA 91362
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exeligen Scientific Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Nov-2016 Completed Out of Business
1. Accelerator/Incubator 28-Oct-2015 Completed Startup
To view Exeligen Scientific’s complete valuation and funding history, request access »

Exeligen Scientific Patents

Exeligen Scientific Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180080051-A1 Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism Inactive 31-Mar-2015 0000000000
EP-3277805-A1 Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism Pending 31-Mar-2015 000000000
JP-2018513681-A Cas9 retroviral integrase and cas9 recombinase system for targeted integration of dna sequences into the genome of a cell or organism Pending 31-Mar-2015 000000000
JP-2021176301-A Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of dna sequence into genome of cell or organism Pending 31-Mar-2015 000000000 0
US-20220315952-A1 Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism Pending 31-Mar-2015 C12N15/85
To view Exeligen Scientific’s complete patent history, request access »

Exeligen Scientific Executive Team (3)

Name Title Board Seat Contact Info
David Aguilar Ph.D Co-Founder & Chief Executive Officer
Ferrukh Sheikh Co-Founder, Chief Financial Officer & President
Mark Stevens Ph.D Co-Founder, President of Research & Development & Chief Scientific Officer
To view Exeligen Scientific’s complete executive team members history, request access »